Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 294.00
Bid: 292.00
Ask: 298.00
Change: -3.00 (-1.01%)
Spread: 6.00 (2.055%)
Open: 294.00
High: 294.00
Low: 294.00
Prev. Close: 298.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

2 Feb 2012 07:00

RNS Number : 6315W
Hutchison China Meditech Limited
02 February 2012
 



 

 

 

 

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

 

 

Total Voting Rights

 

 

London: Thursday, 2 February 2012: For information purposes, Chi-Med hereby notifies the market that as at 31 January 2012, the issued share capital of the Company consisted of 51,794,365 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

 

The above figure of 51,794,365 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the FSA's Disclosure and Transparency Rules.

 

 

Ends

Enquiries

 

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

 

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 20 7638 9571

Mobile: +44 7973 611 888

Mobile: +44 7967 566 919

Lazard & Co., Limited

Paul Gismondi

Nick Fowler

Telephone: +44 20 7187 2000

 

 

About Chi-Med

 

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

 

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVREAKAFEAAAEFF
Date   Source Headline
31st Dec 20207:00 amRNSBlocklisting Six Monthly Return
31st Dec 20207:00 amRNSTotal Voting Rights
30th Dec 202012:00 pmRNSNMPA approval of Surufatinib in China for ep-NET
29th Dec 20207:45 amRNSUS NDA Rolling Submission of Surufatinib Initiated
22nd Dec 20207:00 amRNSChi-Med to Present at JPM
15th Dec 20209:45 amRNSGrant of Share Options under Share Option Scheme
30th Nov 20207:00 amRNSTotal Voting Rights
27th Nov 20207:00 amRNSNotification of Dilution of Voting Rights
17th Nov 20207:00 amRNSUS$100m Equity Investment by CPP Investments
5th Nov 20209:00 amRNSChi-Med to Present HMPL-689 Clinical Data at ASH
30th Oct 202012:00 pmRNSChi-Med to Attend Upcoming Conferences
30th Oct 20207:00 amRNSTotal Voting Rights
30th Sep 20207:00 amRNSTotal Voting Rights
21st Sep 20207:00 amRNSSurufatinib Data at ESMO and in Lancet Oncology
17th Sep 202011:45 amRNSSecond Chinese NDA Acceptance for Surufatinib
4th Sep 20207:00 amRNSChi-Med Initiates Global Phase III Trial
3rd Sep 20207:00 amRNSChi-Med Initiates a Phase II Trial
28th Aug 202011:30 amRNSTotal Voting Rights
24th Aug 20207:00 amRNSClinical Data to be Presented at ESMO 2020
12th Aug 202010:30 amRNSGrant of Share Options under Share Option Scheme
10th Aug 20207:00 amRNSSurufatinib Marketing Authorization Application
30th Jul 202012:00 pmRNSInterim Results and Clinical Update
30th Jul 20207:00 amRNSBlock Admission Application
28th Jul 20207:00 amRNSChi-Med & Lilly Collaborate on Elunate in China
28th Jul 20207:00 amRNSSavolitinib NDA Granted Priority Review in China
24th Jul 20207:00 amRNSChi-Med Initiates HMPL-306 Phase I Trial in China
8th Jul 20208:00 amRNSHolding(s) in Company
7th Jul 20208:00 amRNSHolding(s) in Company
7th Jul 20207:00 amRNSNotification of Dilution of Voting Rights
29th Jun 20207:00 amRNSBlocklisting Six Monthly Return
26th Jun 20207:00 amRNSNotice of Results
25th Jun 20207:15 amRNS$100 Million Equity Investment by General Atlantic
18th Jun 20208:15 amRNSFruquintinib Granted US FDA Fast Track Designation
9th Jun 20207:00 amRNSUS$95m Guangzhou Land Compensation Agreement
4th Jun 20207:00 amRNSContinuation of Phase III FRUTIGA Study
2nd Jun 20204:40 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:37 pmRNSPrice Monitoring Extension
1st Jun 20207:00 amRNSChi-Med Plans to Submit US NDA for Surufatinib
29th May 20201:00 pmRNSChi-Med to Discuss Data Presented at ASCO20
29th May 20207:00 amRNSNDA Acceptance in China for Savolitinib
26th May 20207:00 amRNSChi-Med and BeiGene Enter Clinical Collaboration
14th May 20207:00 amRNSClinical Data to be Presented at ASCO20
11th May 20204:41 pmRNSSecond Price Monitoring Extn
11th May 20204:36 pmRNSPrice Monitoring Extension
11th May 20207:00 amRNSChi-Med to Attend Upcoming Investor Conferences
29th Apr 202011:45 amRNSGrant of Share Options under Share Option Scheme
27th Apr 20202:00 pmRNSResult of AGM
22nd Apr 20209:00 amRNSVirtual Presentations of Surufatinib at AACR
21st Apr 202011:30 amRNSGrant of LTIP Awards and Share Options
17th Apr 20207:00 amRNSSurufatinib Granted FDA Fast Track Designations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.